We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Theravance Biopharma (TBPH - Free Report) . Shares have lost about 17.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Theravance Bio due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Theravance Earnings & Revenues Miss Estimates in Q2
Theravance Biopharma incurred a loss of $1 per share in second-quarter 2020, wider than the Zacks Consensus Estimate of a loss of 95 cents and the year-ago loss of 72 cents as well.
Total revenues of $15 million in the quarter also missed the Zacks Consensus Estimate of $21 million. Revenues declined year over year too, mainly due to lower revenues from the collaboration agreement with J&J and the absence of licensing revenues.
Total revenues in the second quarter comprised collaboration revenues worth $5.5 million from Janssenand $9.5 million from the collaboration agreement with Mylan in relation to Yupelri.
Quarterly Details
Research & development expenses were $62.4 million, up 34.4% from the year-ago quarter, primarily due to higher external cost pertaining to pipeline development.
Selling, general & administrative expenses rose 11.7% to $24.8 million due to higher share-based compensation and employee-related expenses.
As of Jun 30, 2020, Theravance had cash, cash equivalents, marketable securities worth $438.3 million compared with $492.1 million as of Mar 31, 2020.
2020 Outlook
Theravance maintained its financial guidance for 2020. For the full year, the company anticipates operating loss (excluding non-cash share-based compensation) in the range of $205-$225 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision. The consensus estimate has shifted -10.67% due to these changes.
VGM Scores
At this time, Theravance Bio has a poor Growth Score of F, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Theravance Bio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report?
A month has gone by since the last earnings report for Theravance Biopharma (TBPH - Free Report) . Shares have lost about 17.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Theravance Bio due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Theravance Earnings & Revenues Miss Estimates in Q2
Theravance Biopharma incurred a loss of $1 per share in second-quarter 2020, wider than the Zacks Consensus Estimate of a loss of 95 cents and the year-ago loss of 72 cents as well.
Total revenues of $15 million in the quarter also missed the Zacks Consensus Estimate of $21 million. Revenues declined year over year too, mainly due to lower revenues from the collaboration agreement with J&J and the absence of licensing revenues.
Total revenues in the second quarter comprised collaboration revenues worth $5.5 million from Janssenand $9.5 million from the collaboration agreement with Mylan in relation to Yupelri.
Quarterly Details
Research & development expenses were $62.4 million, up 34.4% from the year-ago quarter, primarily due to higher external cost pertaining to pipeline development.
Selling, general & administrative expenses rose 11.7% to $24.8 million due to higher share-based compensation and employee-related expenses.
As of Jun 30, 2020, Theravance had cash, cash equivalents, marketable securities worth $438.3 million compared with $492.1 million as of Mar 31, 2020.
2020 Outlook
Theravance maintained its financial guidance for 2020. For the full year, the company anticipates operating loss (excluding non-cash share-based compensation) in the range of $205-$225 million.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision. The consensus estimate has shifted -10.67% due to these changes.
VGM Scores
At this time, Theravance Bio has a poor Growth Score of F, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Theravance Bio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.